PTEN Hamartoma Tumor Syndrome clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Individuals With Autism and Germline Heterozygous PTEN Mutations

    open to eligible people ages 18 months and up

    The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.

    Los Angeles, California and other locations

Our lead scientists for PTEN Hamartoma Tumor Syndrome research studies include .

Last updated: